AR immunoreactivity was also detected in 40% of benign epithelial neoplasms and 61% of adenocarcinomas [25], as well as in 64% of ovarian neoplasms (8 serous carcinomas, 3 endometrioid carcinomas, 2 mucinous carcinomas, 1 granulosa tumor) [26], obtained from women undergoing oophorectomy. This evidence concerns the gene AR and ovarian neoplasm.